In summary, our data suggest that NQO1 is a marker for low-level oxidative stress, that astrocytic PRDX2 expression is enhanced in brain regions with increased levels of oxygen-derived free radicals in MS, and that PRDX2 expression is not directly influenced by the presence of oxidative stress. Here, PRDX2 is linked to myeloid sarcoma.